PHAT trades 152.0% below Wall Street's consensus target of $17.60.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PHAT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Phathom Pharmaceuticals, Inc. (PHAT) has a Wall Street consensus price target of $17.60, based on estimates from 9 covering analysts. With the stock currently trading at $6.99, this represents a potential upside of +152.0%. The company has a market capitalization of $557M.
Analyst price targets range from a low of $10.00 to a high of $22.00, representing a 68% spread in expectations. The median target of $20.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PHAT trades at a trailing P/E of -2.3x. Analysts expect EPS to grow +27.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ACADACADIA Pharmaceuticals Inc. | $4.4B | $25.43 | $33.83 | +33.0% | Buy | 41.1x | 37 |
 SUPNSupernus Pharmaceuticals, Inc. | $2.5B | $43.39 | $57.60 | +32.7% | Buy | 16.9x | 14 |
 PRGOPerrigo Company plc | $1.9B | $13.84 | $36.20 | +161.6% | Hold | 6.2x | 36 |
 IRWDIronwood Pharmaceuticals, Inc. | $703M | $4.27 | $6.68 | +56.4% | Hold | 3.5x | 30 |
 PTGXProtagonist Therapeutics, Inc. | $8.9B | $138.70 | $176.29 | +27.1% | Buy | 29.7x | 26 |
 MDGLMadrigal Pharmaceuticals, Inc. | $11.8B | $513.02 | $677.00 | +32.0% | Buy | — | 25 |
 TAKTakeda Pharmaceutical Company Limited | $59.8B | $18.81 | — | — | Buy | 0.3x | 6 |
 AZNAstraZeneca PLC | $126.6B | $163.33 | $186.67 | +14.3% | Buy | 15.9x | 41 |
 PFEPfizer Inc. | $160.6B | $28.17 | $28.50 | +1.2% | Hold | 9.5x | 39 |
 MCKMcKesson Corporation | $105.0B | $880.50 | $953.00 | +8.2% | Buy | 19.7x | 31 |
Quick answers to the most common questions about buying PHAT stock.
The consensus Wall Street price target for PHAT is $17.6, representing 152.0% upside from the current price of $6.985. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PHAT has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $17.6 implies 152.0% upside from current levels.
PHAT's current price is $6.985 with a consensus target of $17.6 (152.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $22 for PHAT, while the most conservative target is $10. The consensus of $17.6 represents the median expectation. These targets typically reflect 12-month expectations.
PHAT is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PHAT stock forecast based on 9 Wall Street analysts shows a consensus price target of $17.6, with estimates ranging from $10 (bear case) to $22 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PHAT, with a "Buy" consensus rating and $17.6 price target (152.0% upside). 8 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PHAT analyst price targets range from $10 to $22, a 68% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $17.6 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.